Westfield Capital Management
NKTR icon

Westfield Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Westfield Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,683
Closed -$898K – 249
2019
Q2 		$898K Hold
1,683
– – 0.01% 224
2019
Q1 		$848K Hold
1,683
– – 0.01% 226
2018
Q4 		$830K Sell
1,683
-16,001
-90% -$9.66M 0.01% 226
2018
Q3 		$16.2M Sell
17,684
-30,386
-63% -$25.9M 0.11% 187
2018
Q2 		$35.2M Sell
48,070
-19,525
-29% -$22.5M 0.26% 130
2018
Q1 		$108M Sell
67,595
-85,284
-56% -$110M 0.83% 28
2017
Q4 		$137M Sell
152,879
-89,282
-37% -$52.8M 1.05% 14
2017
Q3 		$87.2M Sell
242,161
-9,438
-4% -$2.95M 0.67% 48
2017
Q2 		$73.8M Sell
251,599
-17,104
-6% -$4.94M 0.63% 53
2017
Q1 		$94.6M Sell
268,703
-10,549
-4% -$2.37M 0.81% 33
2016
Q4 		$51.4M Buy
279,252
+101,845
+57% +$20.7M 0.45% 86
2016
Q3 		$45.7M Buy
177,407
+96,604
+120% +$24.9M 0.37% 92
2016
Q2 		$17.2M Buy
+80,803
New +$18.1M 0.14% 172

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Westfield Capital Management's NKTR Position: Q3 2019 in Review

Westfield Capital Management sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 1,683 shares — an estimated $898K sold.

Westfield Capital Management first reported a position in NKTR in Q2 2016 and held it in 13 quarters. The position peaked at $137M in Q4 2017. 288 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • Westfield Capital Management reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Westfield Capital Management sold 1,683 Nektar Therapeutics shares in Q3 2019, an estimated $898K.
  • Westfield Capital Management first reported a position in Nektar Therapeutics in Q2 2016 and held it in 13 quarters.
  • Westfield Capital Management's Nektar Therapeutics position peaked at $137M in Q4 2017.
  • 288 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on Westfield Capital Management's 13F filing for Q3 2019, filed 8 Nov 2019.